A Phase 3 interventional study of Tislelizumab and Ociperlimab in Non-small Cell Lung Cancer and NSCLC, sponsored by BeiGene. Terminated at 218 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 9th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 28 · Phase 3 10 · Phase 4 2
First in 2017; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 669 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 41 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines: none open now, 1 under way, 1 of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 8th registered.
BeOne Medicines’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2017.
2 of the studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07320105Fujian Cancer HospitalPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | 2027-01-15 |
| NCT07845916Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among BeOne Medicines’s 16 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ociperlimab 900 mg and tislelizumab 200 mg intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.
Drug: Tislelizumab · Drug: Ociperlimab
Participants received pembrolizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.
Drug: Pembrolizumab · Drug: Placebo
Participants received tislelizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.
Drug: Tislelizumab · Drug: Placebo
Japanese participants received ociperlimab 900 mg and tislelizumab 200 mg every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.
Drug: Tislelizumab · Drug: Ociperlimab
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Also known as: BGB-A317
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Also known as: BGB-A1217
Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
Also known as: KEYTRUDA
Placebo infusions will consist of a sterile, normal saline solution.
Overall Survival (OS) in Arms A and B
OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.
Time frame: From randomization until the end of the study. Maximum time on study was 45.0 months
Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)
The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement.
Time frame: From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months.
Safety Run-In Substudy: Serum Concentration of Ociperlimab
Time frame: Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment.
Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator
PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. PFS was a pre-specified secondary endpoint for Arms A and B only. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, unequivocal progression of existing non-target lesions, or new lesions.
Time frame: Up to 45.0 months
Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator
PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Up to 38.9 months
Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator
ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1. ORR was a pre-specified secondary endpoint for Arms A and B only. Complete response is defined as disappearance of all target lesions, disappearance of all nontarget lesions and normalization of tumor marker level, and no new lesions. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, no unequivocal progression of non-target lesions, and no new lesions.
Time frame: Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 45.0 months
Overall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator
ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1.
Time frame: Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 38.9 months
Duration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator
DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method. DOR was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Up to 45.0 months
Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator
DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.
Time frame: Up to 38.9 months
Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL), Physical Functioning, and Pain Scores: European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) in Arms A and B
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health QoL questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life. Included in this outcome measure were evaluation of GHS/QoL, physical functioning, and fatigue. This was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Change From Baseline in EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) Index Score, Dyspnea, Coughing, Hemoptysis, Pain in Chest, Pain in Arms/Shoulders, and Peripheral Neuropathy Scores in Arms A and B
The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. The symptom index scale was calculated by taking the mean of all symptom scale scores, and ranges from 0 to 100. Lower scores indicate an improvement in symptoms. This was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Change From Baseline in European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Visual Analog Scale in Arms A and B
The EQ-5D-5L comprises a descriptive module that includes five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a Visual Analog Scale (VAS). The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes. This was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Time To Deterioration (TTD) in Arms A and B Based on QLQ-LC13 Index Score, Cough, Chest Pain, Dyspnea, Hemoptysis, Arm or Shoulder Pain, and Peripheral Neuropathy
TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥ 10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Up to 45.0 months
Time To Deterioration (TTD) in Arms A and B Based on QLQ-C30 GHS/QoL Score, Physical Functioning, and Fatigue
TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.
Time frame: Up to 45.0 months
Number Of Participants Experiencing Adverse Events (AEs) in Arm A
The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement. This was a pre-specified secondary endpoint for Arm A only.
Time frame: From first dose of study drug up to 30 days after last dose (or 90 days for immune-mediated AEs); maximum treatment duration was 45.0 months
Safety Run-In Substudy: Participants With Anti-Drug Antibodies
Time frame: Up to 38.9 months
Participants were enrolled at 200 centers in 20 countries globally. A safety run-in substudy was conducted to evaluate preliminary safety and tolerability in Japanese participants before Japanese participants were randomized into the study.
| Milestone | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy |
|---|---|---|---|---|
| Started | 287 | 287 | 88 | 7 |
| Received treatment | 286 | 287 | 87 | 7 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 287 | 287 | 88 | 7 |
| Withdrew: Death | 127 | 134 | 43 | 5 |
| Withdrew: Study closed by sponsor | 141 | 136 | 40 | 2 |
| Withdrew: Drug withdrawal by participant | 14 | 16 | 2 | 0 |
| Withdrew: Physician decision | 3 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 0 |
OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.
| months | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Overall Survival (OS) in Arms A and B | 31.9 (25.7 to NA) | 29.4 (25.8 to 35.0) |
The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement.
| Participants | Safety Run-In Substudy |
|---|---|
| Participants With Any Treatment-Emergent Adverse Event (TEAE) | 7 |
| Participants With a TEAE of Grade 3 or Higher | 5 |
| Participants With a Serious TEAE | 4 |
| µg/mL | Safety Run-In Substudy |
|---|---|
| C1D1 Postdose | 390.76 ± 40.1 |
| C1D1 Postdose 24 Hours | 278.72 ± 38.2 |
| C1D1 Postdose 72 Hours | 195.49 ± 29.7 |
| C1D8 | 137.54 ± 49.2 |
| C1D15 | 88.53 ± 55.0 |
| C2D1 Predose | 62.88 ± 73.2 |
| C2D1 Postdose | 445.43 ± 39.8 |
| C5D1 Predose | 135.30 ± 46.0 |
| C5D1 Postdose | 552.30 ± 25.4 |
| C5D8 | 254.46 ± 28.0 |
| C5D15 | 179.15 ± 32.1 |
| C6D1 Predose | 126.31 ± 53.1 |
| C6D1 Postdose | 560.39 ± 35.6 |
| C9D1 Predose | 123.00 |
| C13D1 Predose | 74.40 |
| End of Treatment | 44.15 ± 123.2 |
PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. PFS was a pre-specified secondary endpoint for Arms A and B only. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, unequivocal progression of existing non-target lesions, or new lesions.
| months | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator | 14.3 (11.5 to 16.0) | 10.5 (8.4 to 12.6) |
PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method.
| months | Safety Run-In Substudy |
|---|---|
| Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator | 6.0 (0.6 to NA) |
ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1. ORR was a pre-specified secondary endpoint for Arms A and B only. Complete response is defined as disappearance of all target lesions, disappearance of all nontarget lesions and normalization of tumor marker level, and no new lesions. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, no unequivocal progression of non-target lesions, and no new lesions.
| percentage of participants | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator | 61.0 (55.1 to 66.7) | 48.8 (42.9 to 54.7) |
ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1.
| percentage of participants | Safety Run-In Substudy |
|---|---|
| Overall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator | 28.6 (3.7 to 71.0) |
DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method. DOR was a pre-specified secondary endpoint for Arms A and B only.
| months | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Duration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator | 18.6 (16.5 to 24.2) | 28.3 (16.3 to NA) |
DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.
| months | Safety Run-In Substudy |
|---|---|
| Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator | NA (4.6 to NA) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health QoL questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life. Included in this outcome measure were evaluation of GHS/QoL, physical functioning, and fatigue. This was a pre-specified secondary endpoint for Arms A and B only.
| score on a scale | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Global Health Status/Quality of Life at Cycle 5 | 5.09 ± 21.250 | 4.63 ± 17.044 |
| Global Health Status/Quality of Life at Cycle 7 | 6.67 ± 19.699 | 5.15 ± 17.945 |
| Physical Functioning at Cycle 5 | 2.43 ± 14.726 | 2.18 ± 15.521 |
| Physical Functioning at Cycle 7 | 3.06 ± 15.442 | 3.06 ± 16.094 |
| Fatigue at Cycle 5 | -4.19 ± 19.876 | -3.96 ± 19.043 |
| Fatigue at Cycle 7 | -6.33 ± 19.570 | -5.24 ± 19.406 |
The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. The symptom index scale was calculated by taking the mean of all symptom scale scores, and ranges from 0 to 100. Lower scores indicate an improvement in symptoms. This was a pre-specified secondary endpoint for Arms A and B only.
| score on a scale | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Index Score at Cycle 5 | -3.19 ± 8.438 | -2.17 ± 7.937 |
| Index Score at Cycle 7 | -4.05 ± 8.971 | -2.91 ± 7.475 |
| Coughing at Cycle 5 | -13.15 ± 26.778 | -10.34 ± 27.110 |
| Coughing at Cycle 7 | -13.53 ± 27.890 | -11.87 ± 24.157 |
| Dyspnea at Cycle 5 | -2.89 ± 17.376 | -3.07 ± 15.432 |
| Dyspnea at Cycle 7 | -3.36 ± 17.674 | -2.49 ± 16.637 |
| Hemoptysis at Cycle 5 | -5.08 ± 14.639 | -5.40 ± 16.601 |
| Hemoptysis at Cycle 7 | -6.60 ± 17.607 | -3.14 ± 14.164 |
| Pain in Chest at Cycle 5 | -8.37 ± 22.588 | -5.40 ± 19.731 |
| Pain in Chest at Cycle 7 | -11.06 ± 23.130 | -6.81 ± 20.093 |
| Pain in Arm or Shoulder at Cycle 5 | -2.24 ± 24.911 | 0.00 ± 25.720 |
| Pain in Arm or Shoulder at Cycle 7 | -4.13 ± 24.872 | -1.40 ± 24.858 |
| Peripheral Neuropathy at Cycle 5 | 1.79 ± 18.086 | 1.23 ± 15.701 |
| Peripheral Neuropathy at Cycle 7 | 0.99 ± 17.878 | -1.05 ± 15.258 |
The EQ-5D-5L comprises a descriptive module that includes five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a Visual Analog Scale (VAS). The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes. This was a pre-specified secondary endpoint for Arms A and B only.
| score on a scale | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| VAS at Cycle 5 | 3.04 ± 15.712 | 2.93 ± 14.696 |
| VAS at Cycle 7 | 3.93 ± 14.676 | 4.72 ± 14.707 |
TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥ 10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.
| months | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| Index Score | NA (NA to NA) | NA (NA to NA) |
| Cough | NA (NA to NA) | NA (NA to NA) |
| Chest Pain | NA (NA to NA) | NA (NA to NA) |
| Dyspnea | NA (35.8 to NA) | 25.0 (16.6 to NA) |
| Hemoptysis | NA (NA to NA) | NA (NA to NA) |
| Arm or Shoulder Pain | NA (35.8 to NA) | NA (NA to NA) |
| Peripheral Neuropathy | NA (NA to NA) | NA (NA to NA) |
TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.
| months | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo |
|---|---|---|
| GHS/QoL Score | NA (NA to NA) | NA (NA to NA) |
| Physical Functioning | NA (NA to NA) | NA (NA to NA) |
| Fatigue | NA (NA to NA) | NA (16.6 to NA) |
The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement. This was a pre-specified secondary endpoint for Arm A only.
| Participants | Arm A: Ociperlimab Plus Tislelizumab |
|---|---|
| Participants With Any TEAE | 285 |
| Participants with a TEAE of Grade 3 or Higher | 180 |
| Participants With a Serious TEAE | 150 |
| Participants | Safety Run-In Substudy |
|---|---|
| Safety Run-In Substudy: Participants With Anti-Drug Antibodies | 0 |
Collected over Up to 45.0 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ociperlimab Plus Tislelizumab | 130/287 (45.3%) | 150/286 (52.4%) | 277/286 (96.9%) |
| Arm B: Pembrolizumab Plus Placebo | 137/287 (47.7%) | 113/287 (39.4%) | 267/287 (93%) |
| Arm C: Tislelizumab Plus Placebo | 43/88 (48.9%) | 41/87 (47.1%) | 79/87 (90.8%) |
| Safety Run-In Substudy | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| Event | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 21/286 | 22/287 | 4/87 | 1/7 |
| Afferent loop syndromeInjury, poisoning and procedural complications | 0/286 | 0/287 | 0/87 | 1/7 |
| Incarcerated incisional herniaInjury, poisoning and procedural complications | 0/286 | 0/287 | 0/87 | 1/7 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/286 | 4/287 | 2/87 | 1/7 |
| PemphigoidSkin and subcutaneous tissue disorders | 1/286 | 0/287 | 0/87 | 1/7 |
| Decreased appetiteMetabolism and nutrition disorders | 1/286 | 1/287 | 4/87 | 0/7 |
| Cerebral infarctionNervous system disorders | 1/286 | 3/287 | 3/87 | 0/7 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/286 | 1/287 | 3/87 | 0/7 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 3/286 | 8/287 | 1/87 | 0/7 |
| COVID-19 pneumoniaInfections and infestations | 7/286 | 4/287 | 0/87 | 0/7 |
| Event | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy |
|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 83/286 | 41/287 | 19/87 | 3/7 |
| DiarrhoeaGastrointestinal disorders | 44/286 | 36/287 | 16/87 | 2/7 |
| Decreased appetiteMetabolism and nutrition disorders | 52/286 | 51/287 | 14/87 | 2/7 |
| InsomniaPsychiatric disorders | 34/286 | 23/287 | 8/87 | 2/7 |
| Drug eruptionSkin and subcutaneous tissue disorders | 6/286 | 1/287 | 1/87 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 80/286 | 63/287 | 24/87 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/286 | 49/287 | 19/87 | 0/7 |
| PyrexiaGeneral disorders | 61/286 | 54/287 | 14/87 | 1/7 |
| HypothyroidismEndocrine disorders | 45/286 | 44/287 | 18/87 | 1/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 44/286 | 35/287 | 17/87 | 0/7 |
| Age, Categorical(Participants) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 125 | 128 | 36 | 6 | 295 |
| >=65 years | 162 | 159 | 52 | 1 | 374 |
| Age, Continuous(years) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| Mean | 65.65 ± 8.784 | 65.38 ± 10.114 | 66.26 ± 9.374 | 48.00 ± 16.583 | 65.43 ± 9.698 |
| Sex: Female, Male(Participants) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| Female | 57 | 52 | 21 | 3 | 133 |
| Male | 230 | 235 | 67 | 4 | 536 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 1 | 0 | 12 |
| Not Hispanic or Latino | 278 | 282 | 87 | 7 | 654 |
| Unknown or Not Reported | 1 | 2 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| Asian | 150 | 151 | 45 | 7 | 353 |
| Black or African American | 2 | 0 | 0 | 0 | 2 |
| White | 133 | 133 | 43 | 0 | 309 |
| Not Reported | 0 | 2 | 0 | 0 | 2 |
| Unknown | 1 | 0 | 0 | 0 | 1 |
| Other | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Arm A: Ociperlimab Plus Tislelizumab | Arm B: Pembrolizumab Plus Placebo | Arm C: Tislelizumab Plus Placebo | Safety Run-In Substudy | Total |
|---|---|---|---|---|---|
| Argentina | 0 | 0 | 1 | 0 | 1 |
| United States | 11 | 9 | 3 | 0 | 23 |
| Japan | 19 | 20 | 12 | 7 | 58 |
| Ukraine | 2 | 2 | 1 | 0 | 5 |
| Thailand | 8 | 7 | 3 | 0 | 18 |
| Russia | 3 | 3 | 0 | 0 | 6 |
| Spain | 29 | 24 | 7 | 0 | 60 |
| South Korea | 10 | 14 | 3 | 0 | 27 |
| Netherlands | 8 | 1 | 0 | 0 | 9 |
| Turkey | 26 | 26 | 9 | 0 | 61 |
| China | 109 | 106 | 24 | 0 | 239 |
| Taiwan | 4 | 4 | 1 | 0 | 9 |
| Brazil | 2 | 2 | 1 | 0 | 5 |
| Poland | 2 | 5 | 1 | 0 | 8 |
| Italy | 2 | 2 | 0 | 0 | 4 |
| Georgia | 25 | 32 | 10 | 0 | 67 |
| Australia | 6 | 6 | 4 | 0 | 16 |
| France | 16 | 18 | 8 | 0 | 42 |
| Germany | 4 | 6 | 0 | 0 | 10 |
| Mexico | 1 | 0 | 0 | 0 | 1 |
Showing the first 100 of 218 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from May 2021 to primary completion in May 2025, 48 months.
Results were first posted in May 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Ociperlimab
Carcinoma, Non-Small-Cell Lung →